Collectively, these findings (i) demonstrate the occurrence of dysregulated quality control processes in CKD; (ii) identify a regulatory relationship between HDAC6 and TFEB; and (iii) reveal the possible reno-protective benefits of HDAC6 inhibition through enhanced quality control. Here, HDAC6 is linked to chronic kidney disease.